US cardiorenal-focussed drugmaker Ardelyx (Nasdaq: ARDX) announced that Mike Kelliher, formerly executive vice president, ...

Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the ...

China-based Kelun-Biotech Biopharmaceutical (6990: HK) announced the placement of 5,918,000 H shares under its general ...

Texas-based ImmunoPrecise Antibodies (Nasdaq :IPA) a leader in AI-driven biotherapeutics, closed 22% higher Thursday. The ...

Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

US gene therapy company RegeNXBio (Nasdaq: RGNX) yesterday announced new positive interim data from the Phase I/II AFFINITY ...

Headquartered in Munich, Germany, the company aims to address unmet medical needs in ophthalmology through proprietary gene ...

Japan’s Otsuka (TYO: 4578) today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of ...